Lineage Cell Therapeutics, Inc. (TLV:LCTX)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
423.40
+3.30 (0.79%)
Sep 11, 2025, 5:24 PM IDT
0.79%
Market Cap1.02B
Revenue (ttm)36.77M
Net Income (ttm)-137.84M
Shares Outn/a
EPS (ttm)-0.62
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,242
Average Volume9,113
Open420.10
Previous Close420.10
Day's Range403.00 - 430.00
52-Week Range136.90 - 435.00
Beta1.67
RSI61.73
Earnings DateNov 13, 2025

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2,... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1990
Employees 77
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol LCTX
Full Company Profile

Financial Performance

In 2024, Lineage Cell Therapeutics's revenue was $9.50 million, an increase of 6.19% compared to the previous year's $8.95 million. Losses were -$18.61 million, -13.39% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.